Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia

CONCLUSION: Similar efficacy was demonstrated for eribulin when given in the first-line to beyond the fifth line of chemotherapy in all subtypes of MBC.PMID:33855786 | DOI:10.1111/ajco.13576

Source: Clinical Breast Cancer - April 15, 2021 Category: Cancer & Oncology Authors: Arlene Chan Christopher Lomma HuiJun Chih Elizabeth Blackely Natasha Woodward Daphne Tsoi Kerry Cheong Mitchell Chipman Andrew Redfern Source Type: research